CT 1500
Alternative Names: CT-1500Latest Information Update: 28 Dec 2024
At a glance
- Originator Circadian Therapeutics
- Class Sleep disorder therapies
- Mechanism of Action Purinergic P1 receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Circadian rhythm sleep disorders
Most Recent Events
- 28 Dec 2024 No recent reports of development identified for phase-I development in Circadian rhythm sleep disorders(In volunteers) in Australia (PO, Capsule)
- 07 Jul 2022 Circadian Therapeutics completes a phase-I clinical trial in Circadian rhythm sleep disorders (In volunteers) in Australia (PO) (NCT05070702)
- 08 Nov 2021 Phase-I clinical trials in Circadian rhythm sleep disorders (In volunteers) in Australia (PO) (NCT05070702)